/wp-content/uploads/logo-1.png 0 0 CURC /wp-content/uploads/logo-1.png CURC2020-07-20 10:50:322020-07-20 10:50:32EAU20- Results from the phase III study of nadofaregene
Blog - Latest News
You are here: Home1 / Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer2 / EAU20- Results from the phase III study of nadofaregene
Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572
Phone: (843) 839-1679
Fax: (843) 286-0119
- Dr. Shore Presents Practice-Changing Data In Prostate Cancer / EMBARK points to potential new standard of care for high-risk BCR.
- AUA Chicago April 28 – May 1, 2023- Here We Come
- Perioperative Pembrolizumab Therapy In Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 And KEYNOTE-905/EV-303
- Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
Leave a ReplyWant to join the discussion?
Feel free to contribute!